Real-world HyQvia use for adults with myeloma and weak immunity
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how HyQvia (an immune-boosting medicine given under the skin) is used in real life for adults with multiple myeloma and secondary immune problems. It may help doctors understand what works best and how patients do when HyQvia is used routinely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can (or your legally authorized representative can) agree to take part in the study.
- You have multiple myeloma that needs whole-body (systemic) anti-myeloma treatment.
- You started HyQvia within 30 days of enrollment, or you can start it within 30 days after enrollment (and not after).
- You are 18 years or older, and you have medical records available from your multiple myeloma treatment start.
- Your expected lifespan is more than 6 months, and your daily functioning is limited but not severe (ECOG 0–2).
- You are able and willing to follow the study rules and appointments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
This trial tests a new injectable drug, TQB2029, for people with multiple myeloma. It aims to see if the drug is safe and effective, and may be an option if you have measurable disease and are in relatively good health.
This study tests a new treatment called TQB2934 for people with multiple myeloma that has returned or hasn't gotten better after treatment. The goal is to see if it can help control the disease.
This trial is testing a new drug called QL2109 combined with Darzalex Faspro (daratumumab and hyaluronidase) for people with multiple myeloma that has returned or not responded to earlier treatments. The goal is to see if this combination can better control the cancer compared to standard options.
This trial tests linvoseltamab (a new targeted immune treatment) to see if it’s safe and how well it works in adults with recently diagnosed multiple myeloma who haven’t started treatment yet. Because it’s a “window of opportunity” study, it’s meant to learn early results before standard therapy is fully underway.
This study uses a smartphone or web app to track infections and quality of life in people with multiple myeloma or chronic lymphocytic leukemia who have a weakened immune system. The goal is to create a better screening tool for infections and understand how the disease and treatment affect daily life.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.